Makarova, Natalia, Zhao, Chunxia, Zhang, Yuanyuan et al. · PloS one · 2011 · DOI
Researchers created a vaccine to test whether the body can develop antibodies (immune proteins) against XMRV, a virus that was proposed to be associated with ME/CFS. Mice given the vaccine did produce antibodies against the virus, but these antibodies disappeared quickly—within three weeks. This short-lived immune response might help explain why different studies have found different rates of XMRV in ME/CFS patients.
Understanding whether the immune system can effectively respond to XMRV is crucial for determining if this virus plays a role in ME/CFS and whether vaccines or treatments might be developed. The finding that antibodies wane rapidly may help explain conflicting research results about XMRV prevalence in patient populations, which has been a major point of controversy in ME/CFS research.
This mouse study does not prove that humans naturally infected with XMRV develop similarly short-lived antibodies, nor does it establish that XMRV actually causes ME/CFS. The study also does not demonstrate what happens in chronic XMRV infection or whether short antibody persistence affects long-term viral control in humans.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →